Fractalkine and vascular injury

Expression of fractalkine and its receptor, CX3CR1, in atopic dermatitis: Possible contribution to skin inflammation

“…FKN and CX 3 CR1 represent a novel type of leukocyte trafficking molecule that regulates both adhesive and chemotactic functions 17 . The membrane-bound FKN is able to mediate firm adhesion of CX 3 CR1-expressing leukocytes without requiring selectin-mediated rolling or activation of integrins 18,19 . Furthermore, FKN is released from the cell surface by proteolytic cleavage as soluble FKN (sFKN) that has potent chemoattractant activity for CX 3 CR1 + leukocytes and activates them 12,17,20 …”

Expression of fractalkine and its receptor, CX3CR1, in atopic dermatitis: Possible contribution to skin inflammation

“…FKN and CX 3 CR1 represent a novel type of leukocyte trafficking molecule that regulates both adhesive and chemotactic functions 17 . The membrane-bound FKN is able to mediate firm adhesion of CX 3 CR1-expressing leukocytes without requiring selectin-mediated rolling or activation of integrins 18,19 . , were also examined by ELISA.…”

Antitumor immune activity by chemokine CX3CL1 in an orthotopic implantation of lung cancer model in vivo

“…The secreted CX3CL1 is chemotactic for chemokine receptor, CX3CR1-expressing cells. The membrane form adheres to chemo-attracted cells, resulting in the interaction of dendritic cells, monocytes, T cells and natural killer cells (NK cells) locally (5,6). Initially, the chemotactic activity of CX3CL1 secreted by LLC-CX3CL1 stably expressing CX3CL1 was confirmed (Fig.…”

“…CX3CL1 (also known as fractalkine) is a unique chemokine that functions as an adhesion and chemotactic molecule towards its receptor CX3CR1-expressing cells. Although chemokines activate adhesion molecules, such as integrins, to bind to target cells or the cellular matrix, the interaction of transmembrane CX3CL1-CX3CR1 strongly induces cell-to-cell contact in an adhesion molecule-independent manner (5,6). This study was conducted to examine the efficacy of mouse CX3CL1 for gene therapies by employing an orthotopic transplantation model of mouse lung cancer cells, a model reflecting cancer growth in the lung (7).…”